Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of apof protein in the preparation or screening of diagnostic products for schizophrenia

A schizophrenia and protein technology, applied in the direction of disease diagnosis, medical automation diagnosis, analysis of materials, etc., can solve the problem of undiagnosed schizophrenia and other problems, and achieve the effect of high diagnostic efficiency and stable performance.

Active Publication Date: 2022-07-01
SHANGHAI TIANYIN BIOTECH CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the development of clinical diagnostic markers based on the pathogenesis of schizophrenia is a very urgent need and a huge challenge
There are no studies on the diagnosis of schizophrenia based on abnormal lipid metabolism in patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of apof protein in the preparation or screening of diagnostic products for schizophrenia
  • Use of apof protein in the preparation or screening of diagnostic products for schizophrenia
  • Use of apof protein in the preparation or screening of diagnostic products for schizophrenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0120] 1. Sample Collection

[0121] 110 patients with schizophrenia diagnosed by ICD-11 and 109 normal controls were screened and collected from the Fourth People's Hospital of Wuhu City, Anhui Province. The patients were randomly divided into a discovery set (60 cases) and a validation set (50 cases), and then 61 cases matched with age, gender, and BMI were selected from the normal controls to enter the discovery set, and the remaining 48 cases entered the validation set, that is, the discovery set had a total of 61 cases. There are 60 patients and 61 healthy people, and the validation set contains 50 patients and 48 healthy people. All the enrolled individuals had no physical diseases such as diabetes, malignant tumor, fever, inflammation, etc., and all female individuals were not pregnant. This study has been reviewed by the Ethics Committee of the Fourth People's Hospital of Wuhu City, and the experimental protocol is in line with ethical principles, and all participants...

Embodiment 2

[0178] Example 2 Construction of a diagnostic model

[0179] In the process of constructing the diagnostic model, each discovery set sample in Example 1 is used as a training group to construct a diagnostic model; each verification set sample is used to test the diagnostic efficiency of the model. First, the AUC of each single protein in the discovery set and the validation set in the serum was detected, and the results are shown in Table 4.

[0180] Table 4 AUC of individual proteins

[0181] protein Discovery Set AUC Validation set AUC ApoA4 0.840 0.791 ApoF 0.709 0.708 AGT 0.646 0.763 ACT 0.676 0.710

[0182] Then, age, gender, BMI and various protein variables were arranged and combined to build a logistic regression model in turn. The ROC curve of each group is as follows Figures 4-1 to 4-7 , calculate the AIC and AUC of each model, and the results are shown in Table 3.

[0183] Table 5 Serum Apolipoprotein Combination Con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to schizophrenia diagnostic products, in particular to the use of ApoF protein in the preparation or screening of schizophrenia diagnostic products, the ApoF protein can also be combined with age, gender, BMI, or with ApoA4 protein, AGT protein, AACT The combination of one or more of the proteins is used as an indicator in the preparation or screening of schizophrenia diagnostic products. The present invention discloses for the first time that ApoF protein, ApoA4 protein, AGT protein, AACT protein or their unique peptides are used as biomarkers for diagnosing schizophrenia. It provides a research basis for the preparation and screening of various diagnostic products.

Description

technical field [0001] The present invention relates to schizophrenia diagnostic products, in particular to the use of ApoF protein in the preparation or screening of schizophrenia diagnostic products. Background technique [0002] Schizophrenia is a common mental disorder with a prevalence of around 1%. Patients with schizophrenia have obstacles and abnormalities in perception, thinking, emotion, behavior, etc., and most patients have long-term repeated attacks, which brings great pain to the patients themselves and their families, and causes a heavy burden to the society. [0003] At present, the clinical diagnosis of schizophrenia is mainly based on the comprehensive judgment of the doctor based on the patient's medical history and mental symptoms. This process relies too much on the doctor's experience, and the diagnosis results often vary from person to person. This subjective diagnosis method leads to a high rate of misdiagnosis and delays in the treatment of patients...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68G16H50/20
CPCG01N33/6893G16H50/20G01N2800/302
Inventor 杨旭涵李明慧万春玲
Owner SHANGHAI TIANYIN BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com